Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
Mais filtros











Intervalo de ano de publicação
1.
Trop Anim Health Prod ; 54(4): 241, 2022 Jul 27.
Artigo em Inglês | MEDLINE | ID: mdl-35896831

RESUMO

Capsaicin is a recognized alkaloid that can be used as a flavoring and palatability agent. These effects can increase feed intake in lactating sows during farrowing, especially under thermal stress conditions, and provide antioxidant and immunostimulant activities. The objective of this work was to find out the effects of a capsaicin-based product on the feed intake of sows, immunomodulation, and repercussions on litter performance and the control of piglet diarrhea conditions. A total of 132 pregnant sows and lactating sows and their respective litters were divided into 66 sows each and submitted to one of two possible treatments: a capsaicin-free diet (control group) or capsaicin per meal/day. Capsaicin was mixed with gestation and lactation diets in the proportion of 98.6 g of feed and 1.4 g of capsaicin/kg feed, with the dose administered "on top" of 100 g per treatment day on the first feeding. The sows were treated between 90 days of gestation and 21 days of lactation. Backfat thickness, feed intake during farrowing, colostrum production, IgG colostrum concentration, sow reproductive performance, piglet performance, and diarrhea were evaluated. Compared to the sows in the control group, those that received capsaicin had higher feed intake (+ 0.69 kg/day during lactation, P = 0.008), higher levels of IgG in colostrum (185.75 versus 153.80 mg/mL, P = 0.04), an 11.2% higher litter weight gain, with individual piglet weight gains greater than 5.24% (P = 0.045), and an effective reduction in the frequency of piglet diarrhea on the 10th and 17th days of age (P = 0.013 and P = 0.001, respectively). Capsaicin is an additive with potential effects on the sow's performance, with positive influences on the health and growth of suckling piglets.


Assuntos
Ração Animal , Lactação , Ração Animal/análise , Animais , Peso ao Nascer , Capsaicina/farmacologia , Diarreia/veterinária , Dieta/veterinária , Ingestão de Alimentos , Feminino , Imunoglobulina G , Gravidez , Suínos , Aumento de Peso
2.
J Mycol Med ; 29(3): 253-259, 2019 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-31399349

RESUMO

The search for new antifungal strategies to overcome Candida infections is essential and a matter of public health, due to the high mortality associated to candidiasis, the increasing incidence of resistance to antifungals and the limited number of drugs available for treatment. Several approaches have been exploited in order to develop new antifungal strategies, e.g. the use of natural products, vaccines, and the combination of an antifungal drug to a non-antifungal substance. Nonetheless, issues related to pharmacokinetic parameters, toxicity and costs have been jeopardizing the discovery of new antifungal drugs. An alternative that could overcome these problems would be treating candidiasis with drugs that have been originally developed to treat other diseases. This strategy, known as drug repositioning or drug repurposing, could diminish the incidence of adverse effects and lower the cost of production, since several steps involved in drug discovery and development have already been accomplished. This review presents a set of known drugs that have been exploited as anticandidal agents, such as antidepressant agents, antiepileptic drugs, statins, among others. These substances affect the growth of Candida spp. in vitro, as well as virulence factors such as morphogenesis and biofilm formation. Moreover, some drugs are able to potentiate the anticandidal activity of known antifungal drugs. Drug repositioning appears as a remarkable alternative to increase the pharmacological arsenal against candidiasis, but further studies must be conducted in order to evaluate the real applicability of known drugs in the treatment of these infections.


Assuntos
Antifúngicos/farmacologia , Candida/efeitos dos fármacos , Descoberta de Drogas , Reposicionamento de Medicamentos , Animais , Antidepressivos/uso terapêutico , Antifúngicos/efeitos adversos , Biofilmes/efeitos dos fármacos , Candida/crescimento & desenvolvimento , Candida albicans/efeitos dos fármacos , Candidíase/tratamento farmacológico , Farmacorresistência Fúngica Múltipla , Humanos , Inibidores de Hidroximetilglutaril-CoA Redutases/uso terapêutico , Camundongos , Testes de Sensibilidade Microbiana
3.
J Mycol Med ; 28(2): 314-319, 2018 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-29598974

RESUMO

BACKGROUND: Candida albicans is the most important fungal pathogen that causes infections in humans, and the search for new therapeutic strategies for its treatment is essential. OBJECTIVE: The aim of this study was to evaluate the activity of seven naphthoquinones (ß-lapachone, ß-nor-lapachone, bromide-ß-lapachone, hydroxy-ß-lapachone, α-lapachone, α-nor-lapachone and α-xyloidone) on the growth of a fluconazole-resistant C. albicans oral clinical isolate and the effects of these compounds on the viability of mammalian cells, on yeast's morphogenesis, biofilm formation and cell wall mannoproteins availability. RESULTS: All the compounds were able to completely inhibit the yeast growth. ß-lapachone and α-nor-lapachone were the less cytotoxic compounds against L929 and RAW 264.7 cells. At IC50, ß-lapachone inhibited morphogenesis in 92%, while the treatment of yeast cells with α-nor-lapachone decreased yeast-to-hyphae transition in 42%. At 50µg/ml, ß-lapachone inhibited biofilm formation by 84%, whereas α-nor-lapachone reduced biofilm formation by 64%. The treatment of yeast cells with ß-lapachone decreased cell wall mannoproteins availability in 28.5%, while α-nor-lapachone was not able to interfere on this virulence factor. Taken together, data show that ß-lapachone and α-nor-lapachone exhibited in vitro cytotoxicity against a fluconazole-resistant C. albicans strain, thus demonstrating to be promising candidates to be used in the treatment of infections caused by this fungus.


Assuntos
Antifúngicos/farmacologia , Candida albicans/efeitos dos fármacos , Naftoquinonas/farmacologia , Fatores de Virulência/metabolismo , Animais , Candida albicans/patogenicidade , Farmacorresistência Fúngica , Hifas/efeitos dos fármacos , Camundongos , Células RAW 264.7 , Virulência
4.
J Mycol Med ; 28(1): 137-142, 2018 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-29217144

RESUMO

BACKGROUND: Candidiasis is a major opportunistic fungal infection in humans. The low number of antifungal drugs available to treat Candida infections and the increasing incidence of multidrug resistant (MDR) strains point to an urgent need of identifying new therapeutic options. The role of salivary components can provide insights for the development of new methodologies of control. OBJECTIVE: The aim of this study was to evaluate the ability of histatin-5, a constitutive immunological peptide present in saliva, in reversing fungal MDR phenotype, using a resistant Saccharomyces cerevisiae strain as model of study. RESULTS: A total of 2.5µg and 5µg of histatin-5 revealed to be able to chemosensitize (to revert antifungal resistance) a MDR strain to fluconazole impairing its intrinsic resistance. The presence of histatin-5 decreased the strain growth when associated to fluconazole, and also assisted in the retention of rhodamine 6G within cell cytoplasm. The ATPase activity of Pdr5p, an ABC efflux transporter, was significantly reduced up to 65% within physiological concentration of the peptide. CONCLUSION: Results revealed that histatin-5 is able to revert MDR phenotype and may be considered a potential alternative MDR inhibitor. Since Pdr5p is homologous to Candida albicans CaCdr1p and CaCdr2p, data obtained might be extrapolated to these transporters, inferring that associating fluconazole and histatin-5 may be a useful tool to circumvent failure treatments of infections caused by Candida MDR strains.


Assuntos
Transportadores de Cassetes de Ligação de ATP/efeitos dos fármacos , Antifúngicos/farmacologia , Farmacorresistência Fúngica Múltipla/efeitos dos fármacos , Fluconazol/farmacologia , Histatinas/farmacologia , Proteínas de Saccharomyces cerevisiae/efeitos dos fármacos , Saccharomyces cerevisiae/efeitos dos fármacos , Transportadores de Cassetes de Ligação de ATP/genética , Transporte Biológico , Candidíase/tratamento farmacológico , Farmacorresistência Fúngica Múltipla/genética , Histatinas/química , Histatinas/isolamento & purificação , Humanos , Testes de Sensibilidade Microbiana , Rodaminas/análise , Rodaminas/metabolismo , Saccharomyces cerevisiae/genética , Proteínas de Saccharomyces cerevisiae/genética , Saliva/química
5.
Rev. bras. plantas med ; 16(3): 593-606, jul.-set. 2014. ilus, tab
Artigo em Português | LILACS | ID: lil-722281

RESUMO

Estima-se que aproximadamente 25% das drogas prescritas em todo o mundo são oriundas de espécies vegetais. Dentre as plantas com alto potencial medicinal, se destaca o Hypericum perforatum L. (HP), planta herbácea perene, pertencente à família Hypericaceae. Extratos orgânicos e aquosos de HP têm sido utilizados na medicina popular e em testes pré-clínicos para o tratamento e prevenção de diversas doenças através de efeitos nefroprotetores, atividades antioxidante, antifúngica, ansiolítica, antiviral e cicatrizante. Estudos clínicos indicaram que esta espécie pode ser útil no tratamento de desordens originadas do sistema nervoso central, especialmente na depressão unipolar. HP contém, ao menos, dez classes de compostos biologicamente ativos, dentre eles antraquinonas/naftodiantronas, derivados de floroglucinol, flavonoides, biflavonas, xantonas, óleos voláteis, aminoácidos, vitamina C, cumarinas, taninos e carotenoides. Ao mesmo tempo em que os constituintes possuem relevantes efeitos farmacológicos, os mesmos podem prejudicar, por antagonismo farmacocinético (interação com algumas enzimas do citocromo), a eficácia de outros fármacos. Devido a relevante importância do HP como agente terapêutico, ressalta-se a importância do desenvolvimento de novos estudos com o intuito de elucidar questões ainda controversas acerca do extrato de HP, e.g., dose, melhor horário para colheita, padronização dos extratos, e possíveis efeitos tóxicos, podendo assim, definir claramente os riscos e benefícios da utilização desta planta.


It is estimated that approximately 25% of prescribed drugs are derived from plant species. Among the plants with high medicinal potential, it highlights the Hypericum perforatum L. (HP), perennial herbaceous plant belonging to the family Hypericaceae. Organic and aqueous extracts of HP have been used in folk medicine and in pre-clinical testing for the treatment and prevention of several diseases through effects nefroprotetores, antioxidant, antifungal, anxiolytic, wound healing and antiviral activities. Clinical studies indicated that this specie can be useful in the treatment of central nervous system disorders, especially to unipolar depression. HP contains at least ten classes of biologically active compounds, including anthraquinones/naftodiantronas, phloroglucinol derivatives, flavonoids, biflavones, xanthones, volatile oils, amino acids, vitamin C, coumarins, carotenoids and tannins. At the same time that the secondary metabolites have important pharmacological effects, they can impair the effectiveness of other drugs by pharmacokinetic antagonism.


Assuntos
Plantas Medicinais , Hypericum/metabolismo , Botânica , Extratos Vegetais/análise , Depressão/prevenção & controle , Antidepressivos/farmacologia , Antioxidantes/farmacologia
6.
Water Sci Technol ; 68(7): 1599-606, 2013.
Artigo em Inglês | MEDLINE | ID: mdl-24135110

RESUMO

This study investigated the behaviour of two intermittently fed vertical flow constructed wetlands (one planted with Tifton 85 and the other unplanted) working in parallel, treating raw municipal sewage in Brazil for a population equivalent around 100 inhabitants. Based on a monitoring programme of over 2 years, the following items were evaluated: influence of batch frequency and the presence of Tifton 85 on the wetlands performance in terms of several physico-chemical and biological constituents. The unit with plants performed better than the one without, indicating a positive influence of the presence of plants. More attachment by total and volatile solids and larger amount of bacteria involved in the nitrogen cycle were observed in the planted filter medium, which can explain its higher nitrification and solids removal. The application of a smaller influent volume with a higher batch frequency improved the performance of both units. No signs of medium clogging have been observed in both units. The system simplicity and the good removal efficiency of organic matter, suspended solids, ammonia and helminth eggs indicate its high applicability in small communities in developing countries such as Brazil.


Assuntos
Esgotos , Eliminação de Resíduos Líquidos/métodos , Áreas Alagadas , Amônia , Animais , Bactérias/metabolismo , Brasil , Características da Família , Filtração , Helmintos , Nitritos , Óvulo , Oxirredução , Purificação da Água
7.
J Endocrinol ; 191(2): 459-63, 2006 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-17088415

RESUMO

Peptide YY (PYY)3-36 is a gut-derived hormone, with a proposed role in central mediation of postprandial satiety signals, as well as in long-term energy balance. In addition, recently, the ability of the hormone to regulate gonadotropin secretion, acting at pituitary and at hypothalamus has been reported. Here, we examined PYY3-36 effects on thyrotropin (TSH) secretion, both in vitro and in vivo. PYY3-36-incubated rat pituitary glands showed a dose-dependent decrease in TSH release, with 44 and 62% reduction at 10(-8) and 10(-6) M (P < 0.05 and P < 0.001 respectively), and no alteration in TSH response to thyrotropin-releasing hormone. In vivo, PYY3-36 i.p. single injection in the doses of 3 or 30 cg/kg body weight, administered to rats fed ad libitum, was not able to change serum TSH after 15 or 30 min. However, in fasted rats, PYY3-36 at both doses elicited a significant rise (approximately twofold increase, P < 0.05) in serum TSH observed 15 min after the hormone injection. PYY3-36 treatment did not modify significantly serum T4, T3, or leptin. Therefore, in the present paper, we have demonstrated that the gut hormone PYY3-36 acts directly on the pituitary gland to inhibit TSH release, and in the fasting situation, in vivo, when serum PYY3-36 is reduced, the activity of thyroid axis is reduced as well. In such a situation, systemically injected PYY3-36 was able to acutely activate the thyrotrope axis, suggesting a new role for PYY3-36 as a regulator of the hypothalamic-pituitary-thyroid axis.


Assuntos
Jejum/metabolismo , Peptídeo YY/farmacologia , Adeno-Hipófise/metabolismo , Tireotropina/metabolismo , Animais , Células Cultivadas , Depressão Química , Relação Dose-Resposta a Droga , Leptina/sangue , Masculino , Adeno-Hipófise/efeitos dos fármacos , Ratos , Ratos Wistar , Tireotropina/análise , Tireotropina/sangue , Hormônio Liberador de Tireotropina/metabolismo , Hormônio Liberador de Tireotropina/farmacologia , Tiroxina/sangue , Tri-Iodotironina/sangue
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA